135 related articles for article (PubMed ID: 35740571)
1. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.
Isacoff WH; Cooper B; Bartlett A; McCarthy B; Yu KH
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740571
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.
Yu KH; Ricigliano M; Hidalgo M; Abou-Alfa GK; Lowery MA; Saltz LB; Crotty JF; Gary K; Cooper B; Lapidus R; Sadowska M; O'Reilly EM
Clin Cancer Res; 2014 Oct; 20(20):5281-9. PubMed ID: 25107917
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
4. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
Yu KH; Ricigliano M; McCarthy B; Chou JF; Capanu M; Cooper B; Bartlett A; Covington C; Lowery MA; O'Reilly EM
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30477242
[TBL] [Abstract][Full Text] [Related]
6. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Kamposioras K; Papaxoinis G; Dawood M; Appleyard J; Collinson F; Lamarca A; Ahmad U; Hubner RA; Wright F; Pihlak R; Damyanova I; Razzaq B; Valle JW; McNamara MG; Anthoney A
Acta Oncol; 2022 May; 61(5):583-590. PubMed ID: 35392758
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models.
Hoare O; Fraunhoffer N; Elkaoutari A; Gayet O; Bigonnet M; Roques J; Nicolle R; McGuckin C; Forraz N; Sohier E; Tonon L; Wajda P; Boyault S; Attignon V; Tabone-Eglinger S; Barbier S; Mignard C; Duchamp O; Iovanna J; Dusetti NJ
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069519
[No Abstract] [Full Text] [Related]
8. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.
Filippi R; Lombardi P; Depetris I; Fenocchio E; Quarà V; Chilà G; Aglietta M; Leone F
Expert Opin Pharmacother; 2018 Sep; 19(13):1451-1463. PubMed ID: 30161003
[TBL] [Abstract][Full Text] [Related]
9. Tackling pancreatic cancer with metronomic chemotherapy.
Romiti A; Falcone R; Roberto M; Marchetti P
Cancer Lett; 2017 May; 394():88-95. PubMed ID: 28232048
[TBL] [Abstract][Full Text] [Related]
10. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Head and Neck Cancer Patients Treated with Palliative Oral Metronomic Chemotherapy at a Tertiary Cancer Center in Kerala, India.
Nv V; Muttath G; Jones J; Shringarpure K; Duraisamy K; Deenathayalan VP; Rathi P
Gulf J Oncolog; 2020 May; 1(33):68-74. PubMed ID: 32476653
[TBL] [Abstract][Full Text] [Related]
12. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.
Spugnini EP; Buglioni S; Carocci F; Francesco M; Vincenzi B; Fanciulli M; Fais S
J Transl Med; 2014 Aug; 12():225. PubMed ID: 25143012
[TBL] [Abstract][Full Text] [Related]
13. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
14. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
15. Metronomic Chemotherapy for Metastatic Breast Cancer.
Krajnak S; Battista MJ; Hasenburg A; Schmidt M
Oncol Res Treat; 2022; 45(1-2):12-17. PubMed ID: 34794154
[TBL] [Abstract][Full Text] [Related]
16. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival.
Amantini C; Morelli MB; Nabissi M; Piva F; Marinelli O; Maggi F; Bianchi F; Bittoni A; Berardi R; Giampieri R; Santoni G
Front Oncol; 2019; 9():874. PubMed ID: 31552188
[TBL] [Abstract][Full Text] [Related]
17. Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes.
Kontani K; Hashimoto SI; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
Mol Clin Oncol; 2016 Jun; 4(6):947-953. PubMed ID: 27284428
[TBL] [Abstract][Full Text] [Related]
18. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
20. Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells.
Winter U; Mena HA; Negrotto S; Arana E; Pascual-Pasto G; Laurent V; Suñol M; Chantada GL; Carcaboso AM; Schaiquevich P
PLoS One; 2016; 11(7):e0160094. PubMed ID: 27467588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
